Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Enoyl-CoA hydratase domain-containing protein 3, mitochondrial (ECHDC3) is a mitochondrial enzyme predicted to possess enoyl-CoA hydratase activity, which suggests a role in the hydration step of fatty acid β-oxidation and biosynthesis. It is implicated in fatty acid metabolism and regulation of cellular response to insulin, highlighting possible roles in metabolic health and disease, particularly in the context of Alzheimer disease and familial meningioma risk. ECHDC3 is expressed in many tissues, including metabolic organs and the testis, and is encoded by the ECHDC3 gene located in mitochondria. While it does not have established drug interactions or recognized biomarker roles, its function in fatty acid metabolism may make it relevant for future therapeutic intervention studies.
Not well-characterized; inferred mechanisms from homologs involve hydratase activity in fatty acid metabolism and possibly modulation of insulin sensitivity. Any drug interaction mechanism would likely depend on modulation of fatty acid biosynthesis or insulin responsiveness.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Enoyl-CoA hydratase domain-containing protein 3, mitochondrial (ECHDC3).